Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology sector [8] Core Insights - The report highlights that the pharmaceutical sector, particularly the innovative drug segment, is experiencing a significant bull market, with the innovation drug index outperforming other indices [2][13] - The report emphasizes the strong liquidity in the market, which has led to increased investment in innovative drugs, particularly those related to PD1 and weight loss drugs [2][15] - Future outlook remains optimistic for 2025, focusing on innovative drugs, new technologies, and restructuring of the supply chain [3][16] Summary by Sections 1. Pharmaceutical Core Insights - The pharmaceutical index increased by 1.40% during the week of June 9-13, outperforming both the ChiNext and CSI 300 indices [13] - The innovative drug index rose by 3.07%, indicating strong market performance [50] 2. MNC Cash and Potential Layouts - MNCs have substantial cash reserves, with major companies like Johnson & Johnson and Merck holding over $10 billion in cash, indicating strong purchasing power for potential business development (BD) opportunities [27][25] - The report analyzes MNC revenue sources, highlighting a focus on oncology, metabolism, and mental health, which are areas of high market potential [25][27] 3. Investment Strategies and Thoughts 3.1 Broad Pharmaceuticals - Innovative drugs are a key focus, with a recommendation to explore opportunities in core stocks and those with BD expectations [3][16] - The report identifies specific companies for investment, including major players in the innovative drug space and smaller market cap stocks with promising pipelines [17][18] 3.2 Generic Drugs - The generic drug sector showed a weekly increase of 5.24%, outperforming the broader pharmaceutical index [59] - Top-performing stocks in the generic sector include Yiming Pharmaceutical and Sai Sheng Pharmaceutical, indicating strong market activity [62] 4. Market Review and Hotspot Tracking - The report notes that innovative drugs are becoming the most attractive sector, with significant price increases observed in several companies due to market catalysts [2][15] - Key events, such as the NMPA's inclusion of a new treatment for cardiovascular disease, are highlighted as important developments in the sector [57]

Core Viewpoint - The Hong Kong stock market for innovative pharmaceuticals has seen a significant rebound in 2025, with over 30 companies doubling their stock prices, indicating a potential revaluation of the sector after a prolonged downturn [1][2]. Market Trends - Since the beginning of 2025, the innovative drug sector has become the best-performing segment in the Hong Kong stock market, with companies like 3SBio and Innovent Biologics experiencing substantial market capitalization increases [1]. - The Hang Seng Innovation Drug Index has rebounded to 50% of its historical high, reflecting a recovery from a 76% decline since July 2021 [2][3]. - 82% of the 18A listed pharmaceutical companies in Hong Kong have seen their stock prices rise in 2025 [3]. Investment Activity - There has been a surge in initial public offerings (IPOs) in the innovative drug sector, with 18 companies applying to list on the Hong Kong Stock Exchange since the beginning of the year, including a record 7 in just the first half of June [1]. - The trend of License-out transactions has gained traction, with significant upfront payments, such as 3SBio's $1.25 billion deal, boosting market confidence [4][5]. Capital Flow - There is a noticeable increase in both domestic and international capital flowing into the Hong Kong innovative drug market, with net inflows exceeding HKD 40 billion since 2025 [10]. - The proportion of mainland funds in the Hang Seng Innovation Drug Index has risen from 18% to 22.6% since the beginning of the year [10]. Future Outlook - The market sentiment has shifted positively, with industry leaders discussing expansion and acquisitions rather than survival strategies [3][4]. - Despite the optimism, some investors remain cautious, noting that the current enthusiasm may not be sustainable without systemic support for the industry [11][12].

6月13日恒生指数下跌0.59%，南向资金全天合计成交金额为1582.49亿港元，其中，买入成交792.19亿 港元，卖出成交790.30亿港元，合计净买入金额1.89亿港元。具体来看，港股通（深）累计成交金额 583.33亿港元，买入成交306.56亿港元，卖出成交276.77亿港元，合计净买入金额29.79亿港元；港股通 （沪）累计成交金额999.17亿港元，买入成交485.64亿港元，卖出成交513.53亿港元，合计净卖出金额 27.89亿港元。 成交活跃股方面，今日上榜个股中，南向资金成交金额最多的是山东墨龙，合计成交额97.45亿港元， 阿里巴巴-W、小米集团-W成交额紧随其后，分别成交79.63亿港元、55.14亿港元。以净买卖金额统 计，净买入的个股共有5只，美团-W净买入额为12.18亿港元，净买入金额居首，该股收盘股价下跌 1.99%，建设银行净买入额为4.06亿港元，中石化油服净买入额为8642.16万港元。净卖出金额最多的是 阿里巴巴-W，净卖出33.14亿港元，该股收盘股价下跌2.27%，腾讯控股、中国海洋石油遭净卖出20.64 亿港元、9.19亿港元。 6月13日南向资金成交活跃股 ...

6月13日恒生指数下跌0.59%，报收23892.56点，全天南向资金通过港股通渠道合计净买入1.89亿港元。 证券时报·数据宝统计，6月13日港股通全天合计成交金额为1582.49亿港元，成交净买入1.89亿港元。 具 体来看，沪市港股通成交金额999.17亿港元，成交净卖出27.89亿港元；深市港股通成交金额583.33亿港 元，成交净买入29.79亿港元。 6月13日港股通成交活跃股 | 代码 | 简称 | 类型 | 成交金额（万港元） | 成交净买入（万港元） | 日涨跌幅（%） | | --- | --- | --- | --- | --- | --- | | 00568 | 山东墨龙 | 港股通(沪) | 756964.09 | 4547.99 | 75.65 | | 09988 | 阿里巴巴-W | 港股通(沪) | 601722.19 | -304442.57 | -2.27 | | 00883 | 中国海洋石油 | 港股通(沪) | 414204.61 | -144192.65 | 2.07 | | 03988 | 中国银行 | 港股通(沪) | 335063.09 | -40552.59 ...

Group 1 - On June 13, 2025, Shandong Molong (00568), Alibaba-W (09988), and China National Offshore Oil Corporation (00883) were the top three companies by trading volume in the southbound section of the Shanghai-Hong Kong Stock Connect, with trading amounts of 75.70 billion, 60.17 billion, and 41.42 billion respectively [1] - In the southbound section of the Shenzhen-Hong Kong Stock Connect, Xiaomi Group-W (01810), Shandong Molong (00568), and Alibaba-W (09988) led the trading volume, with amounts of 22.51 billion, 21.76 billion, and 19.46 billion respectively [1] Group 2 - The top active companies in the southbound section of the Shanghai-Hong Kong Stock Connect included Shandong Molong (00568) with a net buying amount of +4547.99 million, while Alibaba-W (09988) and China National Offshore Oil Corporation (00883) had net selling amounts of -30.44 billion and -14.42 billion respectively [1] - In the southbound section of the Shenzhen-Hong Kong Stock Connect, Xiaomi Group-W (01810) recorded a net selling amount of -3.78 billion, while Shandong Molong (00568) had a net buying amount of +46.09 million [1]

Core Insights - Southbound funds recorded a cumulative net inflow of approximately HKD 154.57 billion this week, an increase of about HKD 5.3 billion compared to the previous week [2] - The total trading volume of southbound funds reached HKD 640.38 billion, reflecting a significant increase of approximately 56% week-on-week, while the Hang Seng Index experienced fluctuations [2] Fund Flow Summary - Major net purchases included Meituan-W (HKD 56.75 billion), BYD Company (HKD 29.79 billion), and China Construction Bank (HKD 22.05 billion) [3][5] - Significant net sales were observed in Tencent Holdings (HKD 110.29 billion), Alibaba-W (HKD 70.23 billion), and Xiaomi Group-W (HKD 64.36 billion) [4][5] Stock Performance - Meituan-W saw a cumulative decline of 2.47% this week, with short-term funds continuing to flow in, adding 28.1 million shares over the past five days [5] - BYD Company experienced a cumulative drop of 1.35%, with a slower inflow of short-term funds, adding 15.8 million shares [5] - China Construction Bank increased by 4.81%, with continued inflow of short-term funds, adding 290 million shares [5] - Xinda Biopharmaceuticals rose by 10.32%, with accelerated inflow of short-term funds, adding 28.83 million shares [5] - Tencent Holdings declined by 0.97%, with continued outflow of short-term funds, reducing holdings by 3.69 million shares [5] - Alibaba-W fell by 2.31%, with ongoing outflow of short-term funds, reducing holdings by 10.74 million shares [5] Daily Trading Activity - On June 13, southbound funds recorded a net inflow of approximately HKD 1.89 billion, with the Shanghai-Hong Kong Stock Connect showing a net outflow of HKD 27.89 billion and the Shenzhen-Hong Kong Stock Connect showing a net inflow of HKD 29.79 billion [6] - The trading volume of southbound funds on the same day was about HKD 158.25 billion, accounting for 53.77% of the total trading volume of the Hang Seng Index, indicating a strong market presence [6]

Group 1: Market Overview - Northbound trading recorded a net buy of HKD 1.89 billion, with the Shanghai Stock Connect showing a net sell of HKD 27.89 billion and the Shenzhen Stock Connect showing a net buy of HKD 29.79 billion [1] - The most bought stocks included Meituan-W (03690), China Construction Bank (00939), and Sinopec Oilfield Service (01033), while the most sold stocks were Alibaba-W (09988), Tencent (00700), and CNOOC (00883) [1] Group 2: Stock Performance - Meituan-W (03690) received a net buy of HKD 12.18 billion, driven by the launch of its AI Coding Agent product, which allows users with no coding experience to create websites and software [4] - China Construction Bank (00939) saw a net buy of HKD 4.05 billion, while China Bank (03988) faced a net sell of HKD 4.05 billion, indicating a divergence in bank stock performance [5] - Xiaomi Group-W (01810) experienced a net sell of HKD 7.64 billion, with expectations of narrowing losses in its automotive business by 2025 [7] - Alibaba-W (09988) and Tencent (00700) faced significant net sells of HKD 33.13 billion and HKD 20.63 billion respectively, attributed to lower-than-expected capital expenditures and cloud revenue growth [8] Group 3: Sector Insights - The banking sector is attracting insurance capital due to its high dividend value and the strategic significance of insurance channels for business expansion [5] - The biotechnology sector is facing a sell-off, with companies like Stone Pharmaceutical Group (01093) and Innovent Biologics (01801) experiencing net sells due to a recent wave of equity financing [6] - Bubble Mart (09992) received a net buy of HKD 60.66 million, supported by its strong IP recognition and successful new product launches [6]

Core Viewpoint - The Hong Kong innovative drug sector has achieved a 78% increase as of June 6, 2025, marking the highest half-year growth since 2018, driven by multiple factors including domestic drug approvals and supportive national policies [1][2]. Group 1: 1H25 Review - As of June 6, 2025, the MSCI China Pharmaceutical Index and the Hang Seng Biotechnology Index have risen by 31% and 48% respectively, significantly outperforming the MSCI China Index (up 16%) and the Hang Seng Index (up 19%) [2]. - The innovative drug sector has seen the best performance with a 62% increase, while the pharmaceutical distribution sector has declined by 8% [2]. - The outperformance of the pharmaceutical sector is attributed to its immunity to the "tariff war," continuous improvement in fundamentals, and historically low valuations attracting new capital [2]. Group 2: 2H25 Outlook - The pharmaceutical sector's fundamentals are expected to improve further in 2H25 due to anticipated overseas licensing of domestic innovative drugs, supportive national policies, and rapid growth in innovative drug sales [3]. - The innovative drug sector is recommended as a top choice, particularly companies with strong R&D capabilities and significant commercial potential, such as Innovent Biologics (01801) and BeiGene (06160) [3]. - Innovent Biologics is positioned well with upcoming approvals for key drugs, while BeiGene has multiple catalysts expected in the second half of the year [3]. Group 3: Other Sectors - The medical device sector is expected to benefit from policy-driven demand for high-value consumables and equipment upgrades, with companies like Aikang Medical (01789) and Mindray Medical (300760.SZ) recommended for attention [4]. - The CXO sector shows signs of recovery in new order growth, with companies like WuXi AppTec (02269) and WuXi Biologics (02359) highlighted for their growth potential [4]. - The medical services sector is viewed positively, particularly in traditional Chinese medicine and ophthalmology services [5].

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing positive momentum, driven by significant developments in innovative drug approvals and collaborations, particularly highlighted during the recent ASCO annual meeting and the announcement of potential licensing deals by major companies [1][2]. Group 1: Market Performance - As of June 13, 2025, the CSI Hong Kong Pharmaceutical and Health Comprehensive Index (930965) saw notable increases in key stocks, including WuXi Biologics (02269) up by 5.41%, and Innovent Biologics (01801) up by 3.53% [1]. - The Hong Kong Medical ETF (513700) rose by 1.28%, with a cumulative increase of 12.57% over the past week as of June 12, 2025 [1][2]. Group 2: Industry Developments - On June 12, 2025, China Biopharmaceutical announced at the 46th Goldman Sachs Global Healthcare Conference in Miami that it has received multiple collaboration intentions for its products, indicating a significant upcoming licensing deal [1]. - The ASCO annual meeting showcased the competitiveness and innovation of Chinese pharmaceutical companies, with several impressive results and data presentations [2]. Group 3: ETF and Index Information - The Hong Kong Medical ETF (513700) effectively tracks the CSI Hong Kong Pharmaceutical and Health Comprehensive Index, which includes 50 liquid and large-cap healthcare companies to reflect the overall performance of the sector [2]. - The top ten weighted stocks in the CSI Hong Kong Pharmaceutical and Health Comprehensive Index as of May 30, 2025, include companies like BeiGene (06160) and WuXi Biologics (02269), collectively accounting for 60.77% of the index [3].

Core Viewpoint - Innovent Biologics is set to present multiple clinical study results of mazdutide at the American Diabetes Association's 85th Scientific Sessions, highlighting its potential as a next-generation treatment for Type 2 Diabetes (T2D) and other metabolic diseases [1] Group 1: Clinical Studies and Presentations - The first Phase 3 study of mazdutide in Chinese adults with T2D (DREAMS-1) will be presented orally [1] - Multiple exploratory mechanism of action (MoA) analyses of mazdutide and a preclinical study of IBI3030 will be showcased in poster presentations [1] - The presentations include various studies on mazdutide's effects on liver fat accumulation, hyperuricemia, and cardiovascular risk markers [1][1][1] Group 2: Product Development and Regulatory Status - Mazdutide is currently under review with two New Drug Applications (NDAs) accepted by the National Medical Products Administration (NMPA) [4] - The drug is being evaluated in six Phase 3 clinical studies, with GLORY-1, DREAMS-1, and DREAMS-2 having met their primary endpoints [4] - Innovent has plans for several new clinical studies involving mazdutide, targeting conditions such as metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction (HFpEF) [7] Group 3: Company Overview and Partnerships - Innovent Biologics, founded in 2011, focuses on developing high-quality biopharmaceuticals for various diseases, including oncology and metabolic disorders [4] - The company has launched 15 products and has 3 new drug applications under regulatory review, with 4 assets in Phase III trials and 15 molecules in early clinical stages [4] - Innovent collaborates with over 30 global healthcare companies, including Eli Lilly, to enhance its product offerings and market reach [4]